View in EDS HTML Full Text PDF Full Text

METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.

Saved in:
Bibliographic Details
Title: METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.
Authors: Li S; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; Department of Pharmacy, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010000, China., Chi X; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Li X; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110000, China., Li W; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Yang H; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Cao W; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Zhao Y; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; School of Pharmacy, Henan University, Kaifeng, 475004, China., Zhang X; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Meng R; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; Shanxi University, Taiyuan, 030006, China., Du G; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Zhang D; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. danzhang@imm.ac.cn.; Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. danzhang@imm.ac.cn., Wang J; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. wjh@imm.ac.cn.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. wjh@imm.ac.cn.
Source: Cellular oncology (Dordrecht, Netherlands) [Cell Oncol (Dordr)] 2026 Apr 20; Vol. 49 (3). Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 101552938 Publication Model: Electronic Cited Medium: Internet ISSN: 2211-3436 (Electronic) Linking ISSN: 22113428 NLM ISO Abbreviation: Cell Oncol (Dordr) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42009961
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Li+S%22">Li S</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; Department of Pharmacy, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010000, China.<br /><searchLink fieldCode="AU" term="%22Chi+X%22">Chi X</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110000, China.<br /><searchLink fieldCode="AU" term="%22Li+W%22">Li W</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.<br /><searchLink fieldCode="AU" term="%22Yang+H%22">Yang H</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.<br /><searchLink fieldCode="AU" term="%22Cao+W%22">Cao W</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.<br /><searchLink fieldCode="AU" term="%22Zhao+Y%22">Zhao Y</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; School of Pharmacy, Henan University, Kaifeng, 475004, China.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.<br /><searchLink fieldCode="AU" term="%22Meng+R%22">Meng R</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; Shanxi University, Taiyuan, 030006, China.<br /><searchLink fieldCode="AU" term="%22Du+G%22">Du G</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.<br /><searchLink fieldCode="AU" term="%22Zhang+D%22">Zhang D</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. danzhang@imm.ac.cn.; Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. danzhang@imm.ac.cn.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. wjh@imm.ac.cn.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. wjh@imm.ac.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101552938%22">Cellular oncology (Dordrecht, Netherlands)</searchLink> [Cell Oncol (Dordr)] 2026 Apr 20; Vol. 49 (3). <i>Date of Electronic Publication: </i>2026 Apr 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101552938 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2211-3436 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222113428%22">22113428 </searchLink><i>NLM ISO Abbreviation: </i>Cell Oncol (Dordr) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42009961
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13402-026-01209-2
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Li S
      – PersonEntity:
          Name:
            NameFull: Chi X
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Li W
      – PersonEntity:
          Name:
            NameFull: Yang H
      – PersonEntity:
          Name:
            NameFull: Cao W
      – PersonEntity:
          Name:
            NameFull: Zhao Y
      – PersonEntity:
          Name:
            NameFull: Zhang X
      – PersonEntity:
          Name:
            NameFull: Meng R
      – PersonEntity:
          Name:
            NameFull: Du G
      – PersonEntity:
          Name:
            NameFull: Zhang D
      – PersonEntity:
          Name:
            NameFull: Wang J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 04
              Text: 2026 Apr 20
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2211-3436
          Numbering:
            – Type: volume
              Value: 49
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Cellular oncology (Dordrecht, Netherlands)
              Type: main
ResultId 1